Document is current
Any future updates will be listed below
-
Authors
Kessler, Elizabeth R.
Wulff-Burchfield, Elizabeth
Phillips, Jennifer
Peters, Wesley
McGowan, Tracy
Aggarwal, Pankaj
-
Funding
Funding for this research was provided by:
Janssen Scientific Affairs LLC, a Janssen Pharmaceutical Company of Johnson & Johnson
- License Information
-
More Information
Article History
Received: 21 February 2025
Accepted: 16 April 2025
First Online: 13 May 2025
Declarations
:
: Elizabeth R. Kessler receives funding from Bristol-Myers Squibb, Genentech/Roche, Pfizer, Merck Serono, and Eli Lilly. Elizabeth Wulff-Burchfield reports a consulting role with Astellas Scientific, Exelixis, Bristol-Myers Squibb, Janssen Oncology, AVEO, Aptitude Health, and Targeted Oncology; owns stock in Nektar, Immunomedics; and receives funding from Pfizer and Acerta Pharma/AstraZeneca. Jennifer Phillips is employed by Johnson & Johnson and owns stock in GlaxoSmithKline and Johnson & Johnson. Wesley Peters is employed by Evidera. Tracy McGowan is employed by Johnson & Johnson and owns stock in Johnson & Johnson. Pankaj Aggarwal is employed by Johnson & Johnson and owns stock in Johnson & Johnson.
: All patients were required to provide online consent to participate in the web-based survey. This study was done in accordance with the World Medical Association’s Declaration of Helsinki and was approved by Sterling IRB (IRB #11576). IRB approval of the consent language was also obtained prior to survey implementation.
